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INTRODUCTION AND AIM 
 
 Fludarabine, cyclophosphamide and rituximab (FCR) is the most effective regimen for the 
management of chronic lymphocytic leukemia (CLL), and represents the current standard for 
previously untreated patients who are young and in good physical conditions.1-3 Though the 
majority of CLL patients receiving FCR as frontline therapy are destined to relapse, a subgroup of 
cases may experience durable first remission of their disease.4-6 
 Recently, an impressive array of novel effective therapies has been developed that hold the 
potential of increasingly individualized treatment modalities if patients’ risk could be accurately 
characterized.7-13 Also, in the new scenario of targeted agents for CLL, affordable treatment 
strategies should be patient-risk oriented as well as cost-effective and resource-saving.14 On these 
bases, there is an increasing interest in identifying a priori patients who may maximally benefit 
from a single shot of FCR chemoimmunotherapy.  
 Over the last decade, several molecular prognostic markers capable of stratifying the 
outcome of CLL patients have been identified.15-18 Some of them are widely utilized in the routine 
clinical practice and, individually, have consistently shown prognostic or predictive capability in the 
clinical setting of patients who have received FCR.2,4,5,19,20 However, none of them has been tested 
either alone or in combination with other biomarkers to specifically predict the long-term benefit of 
chemoimmunotherapy. 
 In this observational retrospective study based on a large dataset of FCR-treated CLL, we 
show that the combination of three biomarkers of common use, i.e. immunoglobulin heavy variable 
(IGHV) gene mutation status and FISH abnormalities at chromosomes 11q and 17p, allows to 
segregate a subgroup of CLL patients who may achieve a durable remission after first-line FCR and 








 The study collected 404 progressive and previously untreated CLL patients who 
consecutively received standard FCR as first-line therapy in 19 hematologic centers between 2001 
and 2010. Patients must have fulfilled all of the following criteria for being actively registered in 
the study: i) having a diagnosis of untreated progressive CLL according to NCI or IWCLL/NCI 
criteria;21,22 ii) having received first-line treatment with FCR at standard doses (i.e. no FCR lite);1,2 
iii) having received at least the first dose of the first FCR cycle according to an intention to treat 
approach; iv) having started FCR treatment by 2010, in order to have an adequate follow-up among 
alive patients; v) not receiving maintenance after FCR; and vi) having a minimal set of information, 
including demographic data, treatment indication (development or worsening of anemia and/or 
thrombocytopenia, massive or progressive or symptomatic splenomegaly or lymphadenopathy, 
lymphocyte doubling time, other),21,22 Binet stage at treatment, date of FCR start, date of the last 
dose of FCR, number of FCR courses administered, date of progression according to NCI or 
IWCLL/NCI criteria,21,22 and date of last follow-up or death. The following information were also 
collected for the majority of patients: pre-treatment IGHV mutation status, pre-treatment FISH 
profile (performed within 3 months before FCR treatment start), cause of death, treatment emergent 
second primary malignancies, date and type of next treatments after FCR.  
 
Study design 
 The study was designed as a retrospective observational analysis. Patients received FCR 
between April 2001 and December 2010. The database was locked on June 2014. For sample size 
definition, we assumed a 6-years progression-free survival (PFS) of 38%, a constant hazard of 
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progression of 0.012 per month and a maximum follow-up of 96 months.4,5 Given these 
assumptions, the sample size (n=404) has an 86% and 98% power (two-tailed alpha 5%) to identify 
cases in which the hazard of progression drops to zero after 5 years of follow-up if they account for 
10% or 20% of the entire population, respectively. 
 The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria 
were followed throughout this study.23 Patients provided informed consent in accordance with local 
IRB requirements and Declaration of Helsinki. The study was approved by the Ethical Committee 
of the Ospedale Maggiore della Carità di Novara associated with the Amedeo Avogadro University 
of Eastern Piedmont (Protocol Code 59/CE; Study Number CE 8/11). 
 
Statistical analysis 
 PFS was the primary endpoint and was measured from date of treatment start to date of 
progression according to IWCLL-NCI guidelines (event), death (event) or last follow-up 
(censoring).22 Overall survival (OS) was measured from date of initial presentation to date of death 
from any cause (event) or last follow-up (censoring).22 Time to progression (TTP) was measured 
from date of treatment start to progression according to IWCLL-NCI guidelines (event), death 
(censoring) or last follow-up (censoring).22 Response assessment was according to NCI or IWCLL-
NCI guidelines.21,22 Survival analysis was performed by the Kaplan-Meier method and compared 
between strata using the Log-rank test.24  
 The adjusted association between exposure variables and PFS was estimated by Cox 
regression.25 Cox regression included exposure variables showing an univariate association with 
PFS with a significant level <0.1.26 The proportional hazard assumption was assessed by plotting 
the smoothed Schoenfeld residuals against time.27 The bias corrected c-index and calibration slope 
of the Cox model were calculated through the .632 bootstrap method (1000 resamplings).28,29 The 
heuristic shrinkage estimator was calculated using the formula (model likelihood ratio χ2)  - 
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(number of degree of freedom in the model)/(model likelihood ratio χ2). This approach provides an 
estimate of prediction accuracy of the Cox model to protect against overfitting.26,28 The stability of 
the Cox model was internally validated using bootstrapping procedures.30 In the first step, 1000 
bootstrap samples were generated randomly with replacement from the original CLL population. 
Cox regression was applied to each bootstrap sample with the same covariates as the original 
modeling. The percentage of bootstrap samples for which each covariate was selected as significant 
in the model was then calculated. Percent of selection reflects the prognostic importance of a 
covariate, because it is expected that an important covariate will be selected for the majority of 
bootstrap samples. In the second step, 1000 additional bootstrap samples were generated randomly 
with replacement from the original CLL population. Cox regression was applied to each bootstrap 
sample with the same covariates as the original modeling. For each covariate, the mean standard 
deviation and confidence intervals were computed for the 1000 bootstrap replications. Smooth 
estimate of the hazard of progression according to the time elapsed from treatment start were 
estimated as previously reported.31,32  
 Compared to the Cox-fitted model, recursive partitioning for survival data with censoring 
has the advantage of a more objective and non arbitrary construction of a hierarchical classification 
of covariates.33 The first step in recursive partitioning analysis was to find the best split of the data 
into two groups (nodes) by the predictor variable that captures the most information in the 
variability of PFS. The process was recursively repeated, so succeeding steps find the best splits of 
the data within each of the nodes resulting from prior splits (daughter nodes). The entire dataset was 
considered as the primary node. Three major steps were utilized to derive the best decision tree: i) 
growing an initial tree under the following constraints and stopping rules: a) split criteria of p<0.05 
according to the log-rank test adjusted for multiple comparisons by Bonferroni; b) >20 patients in a 
node in order to be considered for splitting; c) >10 patients in a terminal node; ii) applying a 
pruning algorithm based on the complexity parameter (cp=0.015); and iii) cross-validating the best 
tree size. Ten-fold cross-validation was used to determine the best tree size. The best number of 
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splits was identified as that showing a cross-validation error lower than the smallest cross validation 
error + the corresponding standard error. The stability of the recursive decision tree was validated 
by the random survival forest method.34 An amalgamation algorithm was used to merge terminal 
nodes showing homogenous PFS (further details are available in the Supplementary Appendix).33  
 Relative survival, defined as the ratio between the actuarial survival observed in the CLL 
cohort and the expected survival of the general Italian population matched to CLL patients by sex, 
age and calendar year of diagnosis, was calculated using the Ederer II method.35 The major 
advantage of relative survival is that it provides a measure of the excess mortality experienced by 
CLL patients, irrespective of whether the excess mortality is directly or indirectly attributable to the 
disease. Estimates of the expected survival were calculated utilizing Italian life tables obtained from 
the Human Mortality Database (http://www.mortality.org/, accessed June 18, 2014). 
 Categorical variables were compared by Chi-square and exact tests when appropriate. All 
statistical tests were two-sided. Statistical significance was defined as p value <0.05. The analysis 
was performed with the Statistical Package for the Social Sciences (SPSS) software v.22.0 
(Chicago, IL) and with R statistical package 3.1.2 (http://www.r-project.org).  
 
Immunoglobulin gene mutation analysis and FISH 
IGHV mutation analysis and FISH were performed at the reference laboratory of each 
participating center. IGHV mutation status was tested on tumor gDNA (5 centers) or cDNA (14 
centers) collected at diagnosis or before FCR treatment start, and was assessed according to the 
ERIC guidelines36 by using the BIOMED-2 primers (13 centers),37 primers by Fais et al (5 
centers),38 or an internally developed set of primers (1 center).39 Sequences that differed by more 
than 2% from their corresponding germline were considered as mutated.15,16,36 FISH analysis was 
performed on nuclei extracted from fresh or frozen peripheral blood mononuclear cells collected no 
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more than three months before FCR treatment start. Probes (Abbott) used for FISH analysis were: 
LSI13 and LSID13S319, CEP12, LSIp53, and LSIATM. For each probe, at least 200 interphase 
cells were examined. The presence of 13q deletion, trisomy 12, 11q deletion and 17p deletion 
abnormalities was scored when the percentage of nuclei with the abnormality was above each 
laboratory internal cut offs defined as the mean plus 3 standard deviations of the frequency of 






Characteristics of the study cohort  
 The characteristics of the study cohort (n=404; Table 1) were consistent with those reported 
in CLL receiving FCR as first treatment,2 including age (median: 61 years; >65 years in 33.4% of 
patients), gender (male in 67.8% of patients), stage (progressive Binet A in 10.6% of patients; Binet 
B in 59.7%; Binet C in 29.7%) and number of FCR courses (median: 6; <6 courses in 42.1% of 
patients). Most patients (n=336; 83.2% of the entire cohort) were evaluable for the IGHV mutation 
status (unmutated in 216, 64.3% of patients) and genomic aberrations at treatment requirement 
(n=317; 17p deletion in 30, 9.5% of patients; 11q deletion in 61, 19.2%; +12 in 70, 22.1%; 13q 
deletion in 111, 35.0%). Cases assessable for both IGHV mutations status and FISH (n=317) and 
cases lacking this molecular information (n=87) did not differ with respect to demographic features, 
clinical stage at FCR and treatment indication, thus excluding selection biases. The clinical outcome 
of the study cohort was also consistent with the outcome reported for CLL patients receiving FCR 
as first-line treatment.2 Complete response was documented in 63.9% of assessed cases and partial 
response in 26.9% (Table 1). After a median follow-up of 70 months, 194 patients have progressed 
and 72 have died, accounting for a median PFS of 54.8 months and for a 5-year OS of 81.2% 
(median: not reached) (Figure 1A-1B).  
 
IGHV mutation status and high-risk cytogenetics are independent predictors of PFS after front line 
FCR 
 As a preliminary step towards the construction of a model to predict remission duration in 
FCR-treated CLL, we assessed the impact on PFS of explanatory variables collected at baseline 
10 
	  
before treatment initiation. By univariate analysis (Table 2), patients harboring unmutated IGHV 
genes (5-year PFS: 36.3%; median: 48.2 months) showed a significantly shorter PFS compared to 
IGHV mutated patients (5-year PFS: 58.6%; median: not reached; p=.0005). PFS was also 
significantly shorter in 11q deleted patients (5-year PFS: 18.4%; median: 43.5 months; p=.0106) 
and 17p deleted patients (5-year PFS: 10.9%; median: 22.5 months; p<.0001). Analysis of 
hierarchically disposed FISH abnormalities reproduced the previously described prognostic groups 
in this study cohort (Figure 2).2,5  
 By bivariate analysis, 17p deleted patients had a short PFS, independent of the IGHV 
mutation status (Figure 3). Conversely, the presence of 11q deletion significantly affected PFS 
among IGHV mutated patients, while it was irrelevant among IGHV unmutated cases (Figure 4). By 
multivariate analysis (Table 3), unmutated IGHV genes (HR: 1.65; p=.0099), 11q deletion (HR: 
1.67; p=.0096) and 17p deletion (HR: 3.72; p=<.0001) maintained independent association with 
PFS, thus providing the rationale to utilize these molecular features in the development of a model 
to predict remission duration after FCR. 
 
Most IGHV mutated patients lacking poor risk cytogenetic abnormalities remain free of 
progression after front-line FCR 
 The hierarchical order of relevance in predicting PFS among 17p deletion, 11q deletion and 
IGHV mutation status was established by recursive partitioning analysis (Figure 5A).33 Deletion of 
17p was the most predictive variable in the survival tree, followed by IGHV mutation status and 11q 
deletion. Measure of the variable importance validated the hierarchical order of relevance of the 
molecular lesions established by the recursive partitioning analysis and confirmed the stability of 
the decision tree (Figure 5B).34 Based on the application of the amalgamation algorithm to the 
terminal nodes,33 cases carrying unmutated IGHV genes and cases harboring 11q deletion were 
grouped into a single category because they shared a similar drop of the PFS curve (Figure 5A). 
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This approach allowed to establish a molecular model to classify CLL patients who received FCR 
as first treatment according to the risk of progression. 
 Three CLL subgroups were hierarchically classified (Figure 6A). Disease stage at FCR and 
treatment indication were superimposable across the three risk groups, suggesting that the 
differences in outcome cannot be ascribed to an unintended overtreatment of CLL patients not 
fulfilling the guideline recommended features of active and symptomatic CLL (Table 4). The high-
risk category accounted for 9.5% of the study cohort and included patients harboring 17p deletion 
independent of co-occurring 11q deletion or the IGHV mutation status (5-year PFS: 10.9%; median: 
22.5 months). The intermediate-risk category accounted for 62.1% of the study cohort and included 
patients harboring 11q deletion and/or unmutated IGHV genes in the absence of 17p deletion  (5-
year PFS: 37.9%; median: 51.7 months). The low-risk category accounted for 28.4% of the study 
cohort and comprised patients harboring mutated IGHV genes but lacking both 11q deletion and 
17p deletion (5-year PFS: 71.6%; median: not reached). Consistent with a composition of mixed 
molecular profiles and lack of selection biases, cases not classifiable according to the model 
because of lacking FISH and/or IGHV mutation status (n=87) showed an intermediate clinical 
outcome  (Figure 7). In the tree risk groups, TTP almost matched PFS, indicating that deaths 
without progression did not bias the survival analysis (Figure 8). 
 High- (17p deleted) and intermediate-risk (IGHV unmutated and/or 11q deleted) patients 
showed a constant increase of the hazard of progression over time and almost all were projected to 
relapse after FCR, although at a different rate: 17% per year of follow-up in the high-risk group and 
10% per year of follow-up in the intermediate-risk group (Figure 6A and 9). Conversely, among 
low-risk patients (IGHV mutated without 17p or 11q deletion) the hazard of relapse plateaued at 20 
months after FCR and dropped to 0 after five years of follow-up (Figure 9). Consistently, the PFS 
curve of low-risk patients showed a plateau starting at 5 years from FCR and most of the low-risk 
patients (71.6%) were projected to remain free of progression (Figure 6A). Overall, these data 
indicate that the combination of three biomarkers that are widely tested in the clinical practice 
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allows segregating a sizable subgroup of patients who may achieve a durable remission after front-
line FCR. 
 Low- and intermediate-risk patients who received six FCR cycles showed a significantly 
higher chance of achieving a complete response and a longer PFS compared to patients who 
received less than six FCR cycles, suggesting that a full course of chemoimmunotherapy ensures a 
deeper disease control. The number of FCR courses did not impact on PFS of high-risk patients  
( Figure 10).  
  
IGHV mutated patients lacking poor risk cytogenetic abnormalities have a near-normal life 
expectancy after front line FCR 
 Relative survival analysis was used to provide a measure of the excess mortality experienced 
by CLL patients treated at first-line with FCR, irrespective of whether the excess mortality is 
directly or indirectly attributable to the disease.35 When the demographic effects of age, gender and 
year of treatment were compensated, the 5-year and 10-year survival rates of the whole cohort of 
patients were only 85.3% and 68.7%, respectively, of those expected in the matched normal general 
population (p<.0001) (Figure 1B).  
 Upon OS stratification according to the hierarchical model based on 17p deletion, 11q 
deletion and IGHV mutation status (Figure 6B), the life expectancies of high- (5-year relative 
survival: 60.2%; p<.0001) and intermediate-risk (5-year relative survival: 87.2%; p<.0001) patients 
were significantly impaired compared to that expected in the matched general population, thus 
indicating an excess of deaths related to the disease or treatment complications in these unfavorable 
CLL groups. Conversely, the life expectancy of low-risk patients was similar to that observed in the 
matched normal general population (5-year relative survival: 95.8%; p=.2770) (Figure 6B), 
indicating that neither the disease, nor the complications of treatment, affected survival in this 
favorable CLL group. Consistently, only five patients have died among low-risk patients, including 
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one of progressive disease, one of lung cancer and three of unrelated causes while in remission. In 
addition, the prevalence of treatment-emergent second primary malignancies was significantly 
lower in low-risk patients (3.9%, including one skin basal cell cancer, one lung cancer and one 
thyroid adenoma) compared to intermediate-risk and high-risk cases (12.1% and 19.0%, 






 This study shows that the combination of three biomarkers that are widely tested at 
treatment requirement allows to segregate a subgroup of CLL patients - IGHV mutated without 17p 
or 11q deletion - who: i) accounts for a sizable fraction (28.4%) of progressive previously untreated 
CLL requiring treatment; ii) achieve a durable remission after first-line treatment with FCR; and iii) 
experience an expected survival similar to that of the general population. 
 These findings have potential implications for the design of clinical trials and, possibly, for 
overall disease management of CLL patients. Beyond FCR, significant therapeutic advances have 
occurred in the treatment of CLL and chemotherapy-free approaches are increasingly being 
developed.7-10,12,13 Novel agents such as tyrosine kinase inhibitors show promising activity in CLL 
but are associated with considerable costs and are not affordable in many health care systems if 
applied broadly across large numbers of patients.14,40,41 To responsibly and effectively advance the 
development of these new therapies, they should be targeted specifically to patient subgroups in 
which they can provide the greatest benefit compared to established chemoimmunotherapy 
regimens. Among high-risk CLL with TP53 abnormalities, the activity of tyrosine kinase inhibitors 
appears significantly better than all previous pharmacologic strategies.7-10,12,13 On these bases, 
though per se they do not assure long-lasting remissions and formal head to head comparisons with 
FCR or other chemoimmunotherapy combinations are lacking, tyrosine kinase inhibitors currently 
represent the best treatment option for TP53 disrupted CLL patients and have been approved as 
front-line therapy in this molecular subgroup. Among CLL patients lacking TP53 abnormalities, 
ongoing clinical trials are comparing tyrosine kinase inhibitors vs FCR as front-line treatment. 
Given the highly favorable outcome of IGHV mutated CLL lacking 17p and 11q deletion hereby 
reported following front-line FCR treatment, assessment of whether novel agents provides 




 Long-term toxicities, including treatment emergent second primary malignancies, represent 
a concern for patients treated with FCR.42 In our study population, a proportion of patients 
developed a second primary malignancy, including 3.9% of low-risk patients, 12.1% of 
intermediate-risk patients and 19% of high-risk patients. The low rate of second primary tumors 
among low-risk patients might be explained, at least in part, by the lower requirement of salvage 
treatments, and thus by the low overall load of chemotherapy received by these patients. Beside 
being of limited proportion, second primary malignancies also did not translate into an excess 
mortality in low-risk patients compared to the matched general population, suggesting that the risk 
of death for second primary tumors, as well as other treatment complications, is not increased 
among low-risk patients treated with FCR. 
 The intermediate-risk group of patients represents a case mix warranting further 
stratification, as suggested by the observation that ~20% of intermediate-risk patients progress 
shortly after FCR, while, on the other hand, ~20% of them are projected to remain progression-free 
after 5 years. Additional molecular markers, including gene mutations, have proved to be effective 
in refining CLL prognostication when combined to cytogenetics and IGHV mutation status,43,44 and 
may allow to fine tune the definition and composition of the intermediate-risk group. 
 This study reports on patients treated with FCR in the every-day life clinical practice and 
provides an insight into the “real-world” outcome of patients treated with FCR in the academic and 
community settings. Though not affected by the constrains of clinical trial inclusion criteria, this 
study cohort shows baseline features and outcome superimposable to those described for patients 
treated with FCR within the framework of a clinical study.1,2 On these bases, though the 
retrospective design represents a limitation of this analysis, an external and prospective validation 
of our data is provided by the consistent association between PFS and IGHV mutation status, 17p 
deletion and 11q deletion in multivariable analyses from clinical trials of FCR treated CLL.2,5  
 A strong biologic rationale supports the application of this model to identify patients who 
may benefit mostly from FCR. Indeed, low-risk CLL patients harboring mutated IGHV genes, but 
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lacking 17p or 11q deletion, are those showing the highest sensitivity and deepest response to FCR, 
as documented by the high rate of minimal residual disease (MRD) eradication in this biologic 
subgroup of CLL.45,46 This might stem from a lower degree of genetic complexity and lower rate of 
high-risk subclones that characterize IGHV mutated CLL.47,48 In addition, IGHV mutated patients, 
independent of the levels of disease burden reduction achieved by treatment, generally show a slow 
progression rate in keeping with the lower predisposition of IGHV mutated CLL to proliferate in 
response to microenvironmental stimuli.45 Consistently, 40% (9/22) of the low-risk patients who 
have progresses after FCR, did not require a second-line treatment after progression because of the 
indolent course of the relapsed disease, compared to only 14% (15/102) intermediate-risk patients 
and virtually none (1/27) of high-risk patients.    
 A limitation of this study is the lack of MRD data, which represent a strong independent 
predictor of PFS in CLL patients treated with upfront FCR.45,46 IGHV mutated CLL patients have a 
chance of obtaining negative MRD after few FCR courses,45 suggesting that they are the best 
candidates for an early discontinuation approach. According to our results, however, a full course of 
FCR provides additional PFS benefit to low-risk patients. This observation is consistent with the 
notion that most (~50%) IGHV mutated low-risk patients achieve MRD eradication only after 
completing all six cycles of FCR.45 Studies incorporating MRD eradication monitoring along with 
molecular stratification might allow to derive recommendations about the optimal number of FCR 
courses each patient needs.  
 In the era of personalized medicine, the challenges of CLL treatment will involve correctly 
matching therapy to the unique risk profile of each individual patient. Our data support front-line 
FCR as a highly active option in physically fit patients with progressive CLL whose disease has a 
low-risk molecular profile. Novel chemoimmunotherapy approaches are in development, including 
less toxic combinations (i.e. bendamustine, rituximab, BR) or regimens incorporating second 
generation anti-CD20 monoclonal antibodies (i.e. obinutuzumab and ofatumumab).11,49,50 
Application of our model to CLL cohorts treated with new chemoimmunotherapy approaches will 
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allow to assess whether low-risk patients might equally benefit from BR, and whether second 
generation anti-CD20 monoclonal antibodies might further increase the proportion of low-risk cases 
that will remain progression-free on the long-term. 
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Table 1. Characteristics of the study cohort a 
 All cases n=404 With biomarkers  n=317 
Characteristics Cases % Valid (%) Cases % Valid (%) 
Age <65 years 269 66.6 66.6 222 70.0 70.0 
Age >65 years 135 33.4 33.4 95 30.0 30.0 
Male 274 67.8 67.8 215 67.8 67.8 
Female 130 32.2 32.2 102 32.2 32.2 
Binet A 43 10.6 10.6 39 12.3 12.3 
Binet B 241 59.7 59.7 194 61.2 61.2 
Binet C 120 29.7 29.7 84 26.5 26.5 
Treatment indication       
Development or worsening of anemia and/or thrombocytopenia 79 19.6 19.6 61 19.2 19.2 
Massive or progressive symptomatic splenomegaly or lymphadenopathy 234 57.9 57.9 185 58.4 58.4 
Lymphocyte doubling time 87 21.5 21.5 70 22.1 22.1 
Other 4 1.0 1.0 1 0.3 0.3 
Number of FCR courses 6 234 57.9 57.9 195 61.5 61.5 
Number of FCR courses <6 170 42.1 42.1 122 38.5 38.5 
IGHV       
Mutated 120 29.7 35.7 108 34.1 34.1 
Unnmutated 216 53.5 64.3 209 65.9 65.9 
Missing 68 16.8  - - - 
13q deletion       
Absent 206 51.0 65.0 206 65.0 65.0 
Present 111 27.5 35.0 111 35.0 35.0 
Missing 87 21.5  - - - 
Trisomy 12       
Absent 247 61.1 77.9 247 77.9 77.9 
Present 70 17.3 22.1 70 22.1 22.1 
Missing 87 21.5  - - - 
11q deletion       
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Absent 256 63.4 80.8 256 80.8 80.8 
Present 61 15.1 19.2 61 19.2 19.2 
Missing 87 21.5  - - - 
17p deletion       
Absent 287 71.0 90.5 287 90.5 90.5 
Present 30 7.4 9.5 30 9.5 9.5 
Missing 87 21.5  - - - 
Response to FCR       
Complete response 228 56.4 63.9 186 58.7 66.7 
Partial response 96 23.8 26.9 75 23.7 26.9 
Stable disease 12 3.0 3.3 9 2.8 3.2 
Progressive disease 14 3.5 3.9 7 2.2 2.5 
Not assessable 7 1.7 2.0 2 0.6 0.7 
Missing 47 11.6  38 12.0  
Second treatment after FCR 158 39.1 39.1 126 39.7 39.7 
No second treatment after FCR 246 60.9 60.9 191 60.3 60.3 
Type of second treatment after FCR       
Alemtuzumab-based 18 11.4 13.2 15 11.9 14.3 
Anti-CD20 8 5.1 5.9 6 4.8 5.7 
Anti-CD20+alkylator 28 17.7 20.6 22 17.5 21.0 
Anti-CD20+bendamustine 44 27.8 32.4 34 27.0 32.4 
Anti-CD20+purine analogue 18 11.4 13.2 13 10.3 12.4 
Second line NHL 6 3.8 4.4 5 4.0 4.8 
Other 14 8.9 10.3 10 7.9 9.5 
Unknown 22 13.9  21 16.7  
Second primary malignancy after FCR       
Yes 33 8.2 9.6 28 8.8 10.3	  
No 312 77.2 90.4 243 76.7 89.7	  
Missing 59 14.6  46 14.5  
Cause of death during disease course (including cause of death after disease relapse)       
Infection 12 16.7 17.4 10 19.6 20.4 
Progressive disease 42 58.3 60.9 31 60.8 63.3 
Second primary malignancy 5 6.9 7.2 5 9.8 10.2 
Treatment complication 1 1.4 1.4 1 2.0 2.0 
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Other 9 12.5 13.0 2 3.9 4.1 
Unkown 3 4.2  2 3.9  
a FCR, fludarabine-cyclophosphamide-rituximab treatment; IGHV, immunoglobulin heavy variable gene; NHL non Hodgkin lymphoma	  
Table 2. Univariate analysis of PFS and OS a 
Characteristics 5-year PFS (%) Median PFS 95% CI p 5-year OS (%) 95% CI p 
Age <65 years 46.6 58.1 49.5-66.6 0.0617 86.0 80.9-91.1 0.0001 




Male 42.7 51.6 43.8-59.3 0.3240 82.1 76.8-87.4 0.7575 




Binet A 59.5 64.7 31.8-96.6 0.0848 94.7 84.7-100.0 0.0172 




IGHV Mutated 58.6 nr na 0.0005 88.1 80.7-95.5 0.0359 




No 13q deletion 45.4 55.6 48.3-62.8 0.9041 82.6 79.5-82.7 0.1742 




No Trisomy 12 45.1 55.6 46.3-64.8 0.6188 84.7 81.8-87.6 0.0245 




No 11q deletion 49.4 56.9 47.1-66.6 0.0106 82.5 79.6-85.4 0.9919 




No 17p deletion 48.0 58.9 49.3-68.4 <0.0001 86.0 83.5-88.5 <0.0001 








Table 3. Multivariate analysis of PFSa 
  
 Internal bootstrapping validation 
 
Multivariate analysis  Bootstrap parameters (mean)  
Characteristics HR LCI UCI p  HR LCI UCI 
Bootstrap 
selection 
Age <65 years - - - 
 
 - - - 
39.4% 
Age >65 years 1.23 0.87 1.75 0.2323  1.24 0.87 1.78 
Binet A - - - 
 
 - - - 
55.9% 
Binet B+C 1.57 0.85 2.91 0.1474  1.72 0.88 3.40 
IGHV Mutated - - - 
 
 - - - 
88.0% 
IGHV Unnmutated 1.65 1.12 2.41 0.0099  1.70 1.15 2.52 
No 11q deletion - - - 
 
 - - - 
88.9% 
11q deletion 1.67 1.13 2.46 0.0096  1.67 1.16 2.56 
No 17p deletion - - - 
 
 - - - 
100% 
17p deletion 3.72 2.42 5.71 <0.0001  4.04 2.59 6.31 
a PFS, progression free survival; IGHV, immunoglobulin heavy variable gene; HR, hazard ratio; LCI, lower confidence interval; UCI upper confidence interval 
Shrinkage coefficient: 0.92 
Discrimination: bias-corrected c-index: 0.64; optimism: 0.02 




















   
<65 years 63 70.0  140 71.1  19 63.3 
0.6901 






   
Male 53 58.9  140 71.1  22 73.3 
0.0974 






   
Binet A 16 17.8  22 11.2  1 3.3 
0.0855 
Binet B+C 74 82.2  175 88.8  29 96.7 





   
6 53 58.9  127 64.5  15 50.0 
0.2635 
<6 37 41.1  70 35.5  15 50.0 






   
Development or worsening of anemia and/or thrombocytopenia 18 20.0  40 20.3  3 10.0 
0.4207 
Massive or progressive symptomatic splenomegaly or lymphadenopathy 54 60.0  110 55.8  21 70.0 
Lymphocyte doubling time 17 18.9  47 23.9  6 20.0 






   
Mutated 90 100  11 5.6  7 23.3 
<0.0001 






   
Absent 42 46.7  139 70.6  25 83.3 
<0.0001 






   
Absent 76 84.4  144 73.1  27 90.0 
0.0234 
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Absent 90 100  138 70.1  28 93.3 
<0.0001 






   
Absent 90 100  197 100  0 0 
<0.0001 
Present 0 0  0 0  30 100 





   
No 74 96.1  152 87.9  17 81.0 
0.0500 
Yes 3 3.9  21 12.1  4 19.0 







Figure 1. Kaplan-Meier estimates of progression free survival and overall survival of the 
whole study cohort. Panel A. Progression free survival (PFS) of the whole study cohort. Panel B. 
Overall survival (OS) of the whole study cohort (blue line) relative to the expected OS in the age-, 
sex- and calendar year of treatment-matched general population (black line). p, p-value of the 
comparison between the observed survival and the expected survival.  
 
Figure 2. Kaplan-Meier estimates of progression free survival according to hierarchically 
classified chromosomal abnormalities by FISH. Cases harboring 17p deletion independent of co-
occurring chromosomal abnormalities are represented by the red line. Cases harboring 11q deletion, 
but lacking 17p deletion are represented by the purple line. Cases harboring trisomy 12 but lacking 
17p and 11q deletion are represented by the yellow line. Cases harboring 13q deletion, but lacking 
17p deletion, 11q deletion and trisomy 12 are represented by the blue line. Cases harboring a 
normal FISH karyotype are represented by the green line. p values according to the Log-rank 
statistics 
 
Figure 3. Kaplan-Meier estimates of progression free survival according to 17p deletion 
among IGHV mutated and IGHV unmutated patients. Panel A. Progression free survival (PFS) 
according to 17p deletion status among patients harboring mutated (M) IGHV genes. Cases lacking 
17p deletion are represented by the blue line. Cases harboring 17p deletion are represented by the 
red line. Panel B. Progression free survival (PFS) according to 17p deletion status among patients 
harboring unmutated (UM) IGHV genes. Cases lacking 17p deletion are represented by the blue 
line. Cases harboring 17p deletion are represented by the red line. nr, not reached; na, not 




Figure 4. Kaplan-Meier estimates of progression free survival according to 11q deletion 
among IGHV mutated and IGHV unmutated patients. Panel A. Progression free survival (PFS) 
according to 11q deletion status among patients harboring mutated (M) IGHV genes. Cases lacking 
11q deletion are represented by the blue line. Cases harboring 11q deletion are represented by the 
red line. Panel B. Progression free survival (PFS) according to 11q deletion status among patients 
harboring unmutated (UM) IGHV genes. Cases lacking 11q deletion are represented by the blue 
line. Cases harboring 11q deletion are represented by the red line. nr, not reached; na, not 
applicable; p values according to the Log-rank statistics.  
 
Figure 5. Decision tree resulting from recursive partitioning analysis and amalgamation. Panel 
A. Deletion of 17p and 11q and IGHV mutation status were the factors selected by the algorithm to 
split the patient population in four terminal nodes according to their progression free survival (PFS). 
Presence or absence of 17p deletion independent of co-occurring 11q deletion or unmutated IGHV 
genes was the most significant covariate for the entire study population. Among patients lacking 
17p deletion, the most significant covariate was the IGHV mutation status. Among patients lacking 
both 17p and unmutated IGHV genes, the most significant covariate was 11q deletion. Based on the 
application of the amalgamation algorithm to the terminal nodes, cases harboring unmutated IGHV 
genes and cases harboring 11q deletion were grouped into a single category. Covariates are 
represented from right to left according to their hierarchical order of relevance in splitting the parent 
node into daughter nodes with significantly different survival probabilities. The p value corresponds 
to the log-rank test adjusted for multiple comparisons. The right branch of each split represents the 
presence of the lesion. The left branch of each split represents the absence of the lesion. The 
Kaplan-Meier curves estimate the PFS of patients belonging to each terminal node. n, number of 
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patients in the node. Panel B. The bars represent the variable importance measure for the random 
survival forest model.  
 
Figure 6. Kaplan-Meier estimates of progression free survival and overall survival according 
to the model based on 17p deletion, 11q deletion and IGHV mutation status. Panel A. 
Progression free survival (PFS). Panel B. Overall survival (OS). Cases harboring 17p deletion 
independent of co-occurring 11q deletion or unmutated IGHV genes are represented by the red line. 
Cases harboring unmutated IGHV genes and/or 11q deletion in the absence of 17p deletion are 
represented by the yellow line. Cases harboring mutated IGHV genes in the absence of 11q and 17p 
deletion are represented by the blue line. The black line represents the expected OS in the age-, sex- 
and calendar year of treatment-matched general population. nr, not reached; na, not applicable; p 
values according to the Log-rank statistics.  
 
Figure 7. Kaplan-Meier estimates of progression free survival and overall survival according 
to the model based on 17p deletion, 11q deletion and IGHV mutation status, and including 
cases lacking biological information. Panel A. Progression free survival (PFS). Panel B. Overall 
survival (OS). Cases harboring 17p deletion independent of co-occurring 11q deletion or unmutated 
IGHV genes are represented by the red line. Cases harboring unmutated IGHV genes and/or 11q 
deletion in the absence of 17p deletion are represented by the yellow line. Cases harboring mutated 
IGHV genes in the absence of 11q and 17p deletion are represented by the blue line. Cases lacking 
biological information are represented by the green line. nr, not reached; na, not applicable. 
 
Figure 8. Kaplan-Meier estimates of time to progression (TTP) according to the model based 
on 17p deletion, 11q deletion and IGHV mutation status. Cases harboring 17p deletion 
independent of co-occurring 11q deletion or unmutated IGHV genes are represented by the red line. 
Cases harboring unmutated IGHV genes and/or 11q deletion in the absence of 17p deletion are 
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represented by the yellow line. Cases harboring mutated IGHV genes in the absence of 11q and 17p 
deletion are represented by the blue line. nr, not reached; na, not applicable; p values according to 
the Log-rank statistics.  
 
 
Figure 9. Hazard of progression in relation to the time elapsed from FCR treatment start. 
Cases harboring 17p deletion independent of co-occurring 11q deletion or unmutated IGHV genes 
are represented by the red line. Cases harboring unmutated IGHV genes and/or 11q deletion in the 
absence of 17p deletion are represented by the yellow line. Cases harboring mutated IGHV genes in 
the absence of 11q and 17p deletion are represented by the blue line. 
 
 
Figure 10. Kaplan-Meier estimates of progression free survival (PFS) according to number of 
FCR courses among patient belonging to the low-, intermediate- and high- risk subgroups. 
Cases that received 6 courses are represented by the blue line. Cases received <6 courses are 
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